Skip to main content

Bumetanide (Monograph)

Drug class: Loop Diuretics
VA class: CV702
Chemical name: 3-(Aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid
Molecular formula: C17H20N2O5S
CAS number: 28395-03-1

Medically reviewed by on Mar 2, 2022. Written by ASHP.


Special Alerts:

A standardized concentration for this drug has been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care. The drug is included in a standard concentration list which may apply to an IV or oral compounded liquid formulation. For additional information, see the ASHP website [Web].


  • Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion.

  • Careful medical supervision is required; adjust dosage selection and titration according to the individual patient’s needs. (See Dosage and Administration.)


A sulfonamide loop-type diuretic and antihypertensive agent.

Uses for Bumetanide


Management of edema associated with heart failure or hepatic or renal disease (including nephrotic syndrome).

May be effective in some patients whose condition is unresponsive or refractory to other diuretics.

Considered a diuretic of choice for most patients with heart failure.

Most experts state that all patients with symptomatic heart failure who have evidence for, or a history of, fluid retention generally should receive diuretic therapy in conjunction with moderate sodium restriction, an agent to inhibit the renin-angiotensin-aldosterone (RAA) system (e.g., ACE inhibitor, angiotensin II receptor antagonist, angiotensin receptor-neprilysin inhibitor [ARNI]), a β-adrenergic blocking agent (β-blocker), and in selected patients, an aldosterone antagonist.

Short- and long-term management of edema and ascites associated with hepatic disease (e.g., cirrhosis).

Management of postoperative [off-label] or premenstrual edema [off-label] and edema associated with disseminated carcinoma [off-label].


Management of hypertension [off-label], alone or in combination with other classes of antihypertensive agents.

Not considered a preferred agent for initial management of hypertension according to current evidence-based hypertension guidelines; other agents (i.e., ACE inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, thiazide diuretics) are preferred for initial management.

Some experts state that loop diuretics (e.g., bumetanide, furosemide, torsemide) are preferred over thiazides in patients with moderate to severe chronic kidney disease (CKD) or symptomatic heart failure.

Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).

A 2017 ACC/AHA multidisciplinary hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension. (See Table 1.)

Source: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.

Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).

Table 1. ACC/AHA BP Classification in Adults1200


SBP (mm Hg)

DBP (mm Hg)









Hypertension, Stage 1




Hypertension, Stage 2




The goal of hypertension management and prevention is to achieve and maintain optimal control of BP. However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.

The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) of <130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk. In addition, an SBP goal of <130 mm Hg generally is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg. These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.

Other hypertension guidelines generally have based target BP goals on age and comorbidities. Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk, and have used higher BP thresholds and target BPs in elderly patients compared with those recommended by the 2017 ACC/AHA hypertension guideline.

Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the 2017 ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.

Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient's BP treatment goal.

For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors. ASCVD risk assessment is recommended by ACC/AHA for all adults with hypertension.

ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).

For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.

Adults with hypertension and diabetes mellitus, CKD, or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg. Individualize drug therapy in patients with hypertension and underlying cardiovascular or other risk factors.

In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP. Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in adults with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.

Bumetanide Dosage and Administration


  • Excessive fluid and electrolyte loss may be minimized by monitoring the patient carefully and by initiating therapy with small doses, adjusting dosage carefully, and using an intermittent dosage schedule if possible. (See Boxed Warning.)

  • For the management of fluid retention associated with heart failure, experts state that diuretics should be administered at a dosage sufficient to achieve optimal volume status and relieve congestion without inducing excessively rapid reduction in intravascular volume, which could result in hypotension, renal dysfunction, or both.

  • Supplemental therapy with potassium chloride or potassium-sparing diuretics (e.g., spironolactone) may be necessary for the prevention of hypokalemia and/or metabolic alkalosis in some patients.

Monitoring and BP Treatment Goals

  • Monitor BP regularly (i.e., monthly) during therapy and adjust dosage of the antihypertensive drug until BP controlled.

  • If unacceptable adverse effects occur, discontinue drug and initiate another antihypertensive agent from a different pharmacologic class.

  • Assess patient's renal function and electrolytes 2–4 weeks after initiation of diuretic therapy.

  • If adequate BP response not achieved with a single antihypertensive agent, either increase dosage of single drug or add a second drug with demonstrated benefit and preferably a complementary mechanism of action (e.g., ACE inhibitor, angiotensin II receptor antagonist, calcium-channel blocker). Many patients will require ≥2 drugs from different pharmacologic classes to achieve BP goal; if goal BP still not achieved with 2 antihypertensive agents, add a third drug.


Administer orally, IV, or IM.

Oral Administration

Administer orally as a single daily dose in the morning. May be preferable to administer single daily dose in the evening for a greater diuretic effect. May administer on alternate days or on 3 or 4 consecutive days alternating with drug-free periods of 1 or 2 days.

For optimum therapeutic effect in some patients, may administer twice daily (morning and evening).

Food may delay absorption.

IV or IM Administration

For solution and drug compatibility information, see Compatibility under Stability.

IV or IM administration may be used in patients unable to take oral medication or who have impaired GI absorption; resume oral administration as soon as possible.

Rate of Administration

For direct IV injection, administer slowly over a period of 1–2 minutes.


For IV infusion, dilute in 5% dextrose, 0.9% sodium chloride, or lactated Ringer’s injection; use solutions within 24 hours.


Individualize dosage according to individual requirements and response.

Since the diuretic response following oral or parenteral administration is similar, dosage for oral, IV, or IM administration is identical.

Manufacturer states that bumetanide may be substituted for furosemide in furosemide-allergic patients at approximately a 1:40 ratio (cross-sensitivity between the drugs does not appear to occur). (See Sensitivity Reactions under Cautions.)

Pediatric Patients

Heart Failure† [off-label]

Safety and efficacy not established.

0.015 mg/kg on alternate days to 0.1 mg/kg daily has been used in a limited number of children with heart failure.

In infants 4 days to 6 months of age, maximal diuretic effect was observed at a dosage of 0.035–0.04 mg/kg.



Initially, 0.5–2 mg daily. Repeat dose at 4- to 5-hour intervals until desired response is obtained or maximum dosage of 10 mg daily is reached.

For maintenance therapy, effective dose may be administered intermittently. (See Administration under Dosage and Administration.)

For management of fluid retention associated with heart failure, some experts recommend initiating at a low dosage (e.g., 0.5–1 mg once or twice daily) and increasing dosage (maximum 10 mg daily) until urine output increases and weight decreases, generally by 0.5–1 kg daily.

IV or IM

Initially, 0.5–1 mg. Repeat dose at 2- to 3-hour intervals until desired diuretic response is obtained or a maximum dosage of 10 mg daily is reached.


Initially, 0.5 mg daily.

Some experts state that usual dosage range is 0.5–2 mg daily administered in 2 divided doses.

Prescribing Limits



Maximum recommended by manufacturer and some experts: 10 mg daily.

IV or IM

Maximum recommended by manufacturer: 10 mg daily.

Special Populations

Hepatic Impairment


Use minimum effective dosage; titrate carefully.

Renal Impairment

Oral or IV

Up to 20 mg daily has been administered. IV doses >2 mg needed to achieve a diuretic response in patients with Clcr <5 mL/minute. High dosages may be needed to produce an adequate diuretic response in patients with severe renal impairment (i.e., GFR <10 mL/minute).

Geriatric Patients

Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.

Cautions for Bumetanide


  • Anuria.

  • Marked increases in BUN or Scr or development of oliguria during treatment of progressive renal disease.

  • Hepatic coma or severe electrolyte depletion, until condition is improved or corrected.

  • Known hypersensitivity to bumetanide or any ingredient in the formulation.



Fluid, Electrolyte, and Cardiovascular Effects

Careful etiologic diagnosis should precede use of any diuretic. Titrate dosage carefully; excessive dosage, administration frequency, or prolonged therapy may lead to profound water loss, electrolyte depletion, dehydration, reduction in blood volume, and circulatory collapse with the possibility of vascular thrombosis and embolism, especially in geriatric patients. (See Boxed Warning.)

Observe carefully for signs of electrolyte depletion, especially hypokalemia. Excessive fluid and electrolyte loss may be minimized by careful monitoring and initiating therapy with small doses, careful dosage adjustment, and an intermittent dosage schedule if possible.

Hypokalemia may occur; evaluate serum potassium concentration periodically. Hypokalemia is particularly likely and important to prevent in patients with hyperaldosteronism and normal renal function, hepatic cirrhosis and ascites, potassium-losing renal diseases, or certain diarrheal conditions and may require particular attention in patients with heart failure receiving cardiac glycosides and diuretics, those with a history of ventricular arrhythmias, and those with other conditions in which hypokalemia represents a risk. (See Hepatic Impairment under Cautions.)

Periodic determination of other serum electrolyte concentrations recommended for patients receiving high dosages or chronic therapy, especially when sodium intake is restricted. If excessive diuresis and/or electrolyte abnormalities occur, discontinue therapy or reduce dosage until corrected.


Produces ototoxicity in animals at high dosages. Serum concentrations associated with ototoxicity in humans unlikely; consider possibility of ototoxicity following IV administration, especially at high dosages, after too rapid administration, in patients with impaired renal function, and/or in patients receiving other ototoxic drugs (e.g., aminoglycosides). (See Specific Drugs under Interactions.)


Rare postmarketing experience reports; monitor regularly.

Sensitivity Reactions


Patients allergic to sulfonamides may be hypersensitive to bumetanide; use with extreme caution. Does not appear to exhibit cross-sensitivity in patients allergic to furosemide.

General Precautions

Electrolyte Effects

Hypomagnesemia, hypocalcemia, and/or hypophosphatemia may occur.

Endocrine Effects

Possible effects on glucose metabolism should be considered. Changes in plasma insulin, glucagon, or growth hormone concentration or in glucose tolerance or diabetic control generally have not been observed; diuretic-induced hyperglycemia occurs rarely. May result from potassium depletion, which has been associated with impaired insulin secretion.

Other Effects

Blood dyscrasias (especially thrombocytopenia), liver damage, or idiosyncratic reactions have been reported occasionally.

Hyperuricemia may occur; most reported cases have been asymptomatic.

Specific Populations


Category C.


Not known whether bumetanide is distributed into milk. Use not recommended.

Pediatric Use

Safety and efficacy not established in children <18 years of age.

Has been used effectively as a diuretic for up to 40 weeks in a limited number of infants 2 weeks to 7 months of age with congenital heart disease and heart failure.

Use with caution in critically ill or jaundiced neonates at risk for kernicterus; in vitro studies indicate bumetanide may displace bilirubin from albumin. (See Distribution: Special Populations, under Pharmacokinetics.)

Elimination appears to be slower in neonates than in adults, possibly because of immature renal and hepatobiliary functions. (See Elimination: Special Populations, under Pharmacokinetics.)

Geriatric Use

Response in patients ≥65 years of age does not appear to differ from that in younger adults; however, use with caution due to greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy observed in geriatric patients. (See Fluid, Electrolyte, and Cardiovascular Effects under Cautions.) Monitor renal function.

Hepatic Impairment

Use with caution in patients with hepatic cirrhosis and ascites; sudden alterations in electrolyte balance may precipitate hepatic encephalopathy and coma. Therapy in such patients is best initiated in the hospital with small doses and careful monitoring of clinical status and electrolyte balance. Supplemental potassium and/or concomitant potassium-sparing diuretics (e.g., spironolactone) may be used to prevent hypokalemia and metabolic alkalosis.

Renal Impairment

Patients with renal impairment may require high dosages to achieve an adequate diuretic response. (See Renal Impairment under Dosage and Administration.)

The risk of adverse effects (e.g., ototoxicity) at high dosages should be considered. (See Ototoxicity under Cautions.)

Common Adverse Effects

Muscle cramps, dizziness, hypotension, headache, nausea, encephalopathy, hyperuricemia, hypochloremia, hypokalemia, azotemia, hyponatremia, increased serum creatinine, hyperglycemia.

Interactions for Bumetanide

Specific Drugs




Anticoagulants, oral (e.g., warfarin)

Plasma prothrombin activity or warfarin metabolism not affected

Antihypertensive agents

Additive antihypertensive effect

Reduction in dosage of both drugs may be required.

Concomitant therapy generally used to therapeutic advantage; orthostatic hypotension may occur.

Cardiac glycosides (e.g., digoxin)

Possible electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) may predispose to digitalis toxicity, possibly fatal cardiac arrhythmias

Renal excretion and serum digoxin concentrations not affected

Monitor electrolytes; correct hypokalemia


Increased diuretic and natriuretic effects

Diuretics, potassium- sparing (e.g., amiloride, spironolactone, triamterene)

Possible reduction in potassium loss

Concomitant therapy may be used to therapeutic advantage


Decreased diuretic and natriuretic effect

Concomitant therapy not recommended

If concomitant therapy is necessary, increased bumetanide dosage may overcome decreased diuretic effect .

Other drugs causing potassium loss (corticosteroids, corticotropin, amphotericin B)

Additive hypokalemic effects

Monitor electrolytes; correct hypokalemia


Reduced renal clearance of lithium and increased risk of lithium toxicity

Concomitant use generally contraindicated; if concomitant therapy is necessary, monitor serum lithium concentrations and adjust dosage

Nondepolarizing neuromuscular blocking agents (e.g., atracurium besylate, tubocurarine chloride)

Potential for prolonged neuromuscular blockade, possibly due to potassium depletion and/or decreased urinary excretion of neuromuscular blocking agent

Clinical importance unknown; use with caution

Nephrotoxic drugs

Possible increased nephrotoxic effects; no clinical experience to date

Avoid concomitant use

Ototoxic drugs (e.g., aminoglycoside antibiotics, cisplatin)

Possible additive ototoxic effect, especially in patients with impaired renal function

Avoid concomitant parenteral administration of bumetanide and aminoglycoside antibiotics, except in life-threatening conditions


Decreased diuretic and natriuretic effects, inhibition of bumetanide-induced increase in plasma renin activity

Avoid concomitant use

Bumetanide Pharmacokinetics



Rapidly and almost completely (85–95%) absorbed following oral administration; peak plasma concentrations generally attained within 0.5–2 hours.

Appears to be completely absorbed following IM administration.


Diuresis begins within 30–60 minutes following oral administration, about 40 minutes following IM administration, and within a few minutes following IV administration. Peak diuretic activity generally occurs within 1–2 hours following oral or IM administration and within 15–30 minutes after IV administration.


Diuresis is dose-dependent and generally complete within 4–6 hours following oral or IM administration.

Following IV administration, diuresis generally persists for 2–3 hours.


Limited data suggest food may delay GI absorption.

Special Populations

Bioavailability appears similar in patients with impaired renal or hepatic function.



Distribution has not been fully characterized.

Not known whether bumetanide crosses the blood-brain barrier or the placenta or is distributed into milk.

Bumetanide and its metabolites are distributed into bile. Following oral administration of radiolabeled bumetanide in one patient with a biliary T tube in place, 1.8% of the dose was distributed into bile as unchanged drug and 12.6% as metabolites.

Does not appear to bind to erythrocytes.

Following IV administration in healthy adults, the steady-state volume of distribution (Vss) ranged from 9.45–19.7 L and the volume of distribution of the central compartment (Vc) ranged from 3.26–5.84 L.

Plasma Protein Binding

Approximately 93–96%.

Special Populations

Following IV administration in neonates, the mean volume of distribution ranged from 0.26–0.38 L/kg.

May increase serum concentrations of free (unbound) bilirubin by displacement from albumin when administered to critically ill neonates.

Protein binding may be decreased in patients with renal impairment; binding appears to be correlated with plasma albumin concentration.

Vss may be increased in patients with renal impairment.

Vss may be decreased in patients with hepatic impairment.



Bumetanide is partially metabolized by oxidation in the liver to at least 5 metabolites. Major urinary metabolite is the 3′-alcohol derivative. The major metabolite excreted in bile and/or feces is the 2′-alcohol derivative. Minor metabolites include the 4′-alcohol, N-desbutyl, and 3′-acid derivatives.

Metabolites in urine and bile are present as conjugates, principally glucuronide conjugates. Conjugates of bumetanide and its metabolites do not appear in feces.

Elimination Route

Bumetanide and its metabolites are excreted principally in urine. Renal excretion appears to occur mainly via glomerular filtration; tubular secretion also may occur.

Following oral or IV administration in healthy adults, about 80% of a dose is excreted in urine and 10–20% in feces within 48 hours; about 50% of a dose is excreted unchanged in urine. Excreted in feces almost completely as metabolites, apparently via biliary elimination; less than 2% of a dose is excreted unchanged in feces within 48 hours.


1–1.5 hours in healthy adults following oral administration.

Plasma concentrations generally decline in a monophasic or biphasic manner; however, plasma concentrations may decline in a triphasic manner following IV administration.

Following IV administration in adults with normal renal and hepatic function, t½α averages 5–6.9 minutes, t½β averages 46–47 minutes, and t½γ averages 3.1–3.4 hours.

Special Populations

Clearance decreased in patients with impaired renal function, with or without concurrent hepatic impairment; in patients with only renal impairment, nonrenal clearance of the drug is about 90% or more of total body clearance. Serum concentrations may be higher and the terminal elimination half-life prolonged in patients with impaired renal and/or hepatic function.

In neonates and infants, elimination appears slower than in older pediatric patients and adults, possibly because of immature renal and hepatobiliary functions. Mean serum elimination half-life decreased considerably during the first month of life from 6 hours in neonates to 2.4 hours in infants 1 month of age. Mean serum elimination half-life is 2.5 and 1.5 hours in infants younger than 2 months of age and in those 2–6 months of age, respectively. Limited data indicate that the apparent elimination half-life may be prolonged to about 6 hours (with a range up to 15 hours) after IV administration in premature or full-term neonates with respiratory disorders.





15–30°C in tight, light resistant containers.



15–30°C; protect from light.

If diluted with infusion solution, use within 24 hours of preparation.


For information on systemic interactions resulting from concomitant use, see Interactions.


Physically and chemically compatible in glass and PVC containers.

Solution CompatibilityHID


Dextrose 5% in water

Sodium chloride 0.9%

Ringer’s injection, lactated

Drug Compatibility
Admixture CompatibilityHID




Dobutamine HCl

Y-Site CompatibilityHID


Allopurinol sodium




Caspofungin acetate

Ceftaroline fosamil

Cisatracurium besylate


Dexmedetomidine HCl

Diltiazem HCl



Etoposide phosphate


Gemcitabine HCl

Granisetron HCl

Hetastarch in lactated electrolyte injection (Hextend)


Melphalan HCl

Meperidine HCl

Micafungin sodium

Milrinone lactate

Morphine sulfate


Pemetrexed disodium

Piperacillin sodium–tazobactam sodium


Remifentanil HCl



Vinorelbine tartrate


Fenoldopam mesylate

Midazolam HCl



  • Loop diuretic with a rapid onset and short duration of action.

  • Approximately 40 times the diuretic activity of furosemide on a weight basis; relative potency may vary with different dosages and/or routes of administration.

  • Decreases electrolyte reabsorption by inhibiting the active chloride and sodium transport systems in the ascending limb of the loop of Henle to inhibit sodium and chloride reabsorption.

  • Increases urinary excretion of sodium, chloride, potassium, hydrogen, calcium, magnesium, ammonium and possibly phosphate and bicarbonate.

  • The chloruretic effect of the drug is greater than its natriuretic effect, and its effect on urinary calcium and magnesium excretion is less than that on sodium excretion.

  • Increases potassium secretion in the distal renal tubule in a dose-related manner secondary to increased sodium load in the tubule.

  • Induces phosphaturia and bicarbonate excretion; appears to inhibit sodium phosphate-linked transport in the proximal renal tubule.

  • Decreases uric acid excretion and increases serum uric acid concentration.

  • Produces renal vascular dilation and substantially increases renal blood flow.

  • Produces variable but substantial increases in plasma renin activity (PRA).

  • Produces hypotensive effects and decreases body weight resulting from decreased plasma volume.

  • Reduces mean pulmonary venous pressure, left ventricular end-diastolic pressure, mean pulmonary artery pressure, and mean right atrial pressure in patients with valvular heart disease.

  • Reduces cardiac output, cardiac index, stroke volume, stroke index, and diastolic pressures in patients with coronary artery disease.

Advice to Patients

  • Importance of informing patients to report any signs and symptoms of electrolyte imbalance (weakness, dizziness, fatigue, faintness, mental confusion, lassitude, muscle cramps, headache, paresthesia, thirst, anorexia, nausea, and/or vomiting) to their clinician.

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.

  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.

  • Importance of informing patients of other important precautionary information. (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name



Dosage Forms


Brand Names




0.5 mg*

Bumetanide Tablets

1 mg*

Bumetanide Tablets

2 mg*

Bumetanide Tablets



0.25 mg/mL*

Bumetanide Injection

AHFS DI Essentials™. © Copyright 2023, Selected Revisions March 2, 2022. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

Reload page with references included

Frequently asked questions